Thursday, March 15, 2012
Biosimilar Insulins
Biocon is conducting Phase-3 trials of recombinant human insulin (biosimilar of Novo Nordisk’s Novolog) in Europe and global Phase-1 trials for glargine (biosimilar of Sanofi-Aventis’ Lantus). Biocon will continue to develop other biosimilars — aspart (biosimilar of Novo Nordisk’s Novolog) and lispro (biosimilar of Eli Lilly’s Humulog)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment